CDNA
CareDx, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$85.40
−3.47%Year over year
Reported trailing growth
- Revenue
- +38.9%
- EBITDA
- +249.6%
- EBIT
- -91.8%
- EPS
- +91.3%
- Free cash flow
- +62.0%
- Operating cash flow
- +62.2%
Forward estimates
Based on analyst estimates
- Revenue
- +11.8%
- EBITDA
- +358.8%
- EPS
- -40.7%
Three-year CAGR
- Revenue
- +5.7%
- EBITDA
- +86.3%
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +14.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026